Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14674417 | 1.00 | PDGFRB (0.56) | PDGFRBMEN1KMT2ATGM2MDM2 | |
| SCHEMBL14674036 | 0.90 | MEN1 (0.69) | MEN1KMT2AMDM2NPC1FLT3 | |
| SCHEMBL29638272 | 0.90 | MEN1 (0.69) | MEN1KMT2AMDM2NPC1FLT3 | |
| SCHEMBL14674037 | 0.90 | MEN1 (0.69) | MEN1KMT2AMDM2NPC1FLT3 | |
| SCHEMBL14675012 | 0.86 | MDM2 (0.49) | PDGFRBMEN1KMT2ATGM2MDM2 | |
| SCHEMBL14679950 | 0.86 | MEN1 (0.56) | PDGFRBMEN1KMT2ANPC1FLT3 | |
| SCHEMBL14675013 | 0.86 | MDM2 (0.49) | PDGFRBMEN1KMT2ATGM2MDM2 | |
| SCHEMBL14674773 | 0.86 | NPC1 (0.53) | PDGFRBMEN1KMT2ANPC1FLT3 | |
| SCHEMBL14674772 | 0.86 | NPC1 (0.53) | PDGFRBMEN1KMT2ANPC1FLT3 | |
| SCHEMBL14674292 | 0.84 | NPC1 (0.74) | PDGFRBMEN1KMT2ATGM2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | claimed |
| US-8877946-B2 | Benzylidene-indolinone compounds and their medical use | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-11-04 | — | — | US | disclosed |
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035364-A1 | BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE | ERBB2, ABL1, IGF1R | PDGFRB 11/4885MEN1 1058/4885KMT2A 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.